Cargando…

Correction to: Olipudase Alfa in Non-CNS Manifestations of Acid Sphingomyelinase Deficiency: A Profile of Its Use

Detalles Bibliográficos
Autor principal:	Syed, Yahiya Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480271/ https://www.ncbi.nlm.nih.gov/pubmed/37493879 http://dx.doi.org/10.1007/s40261-023-01293-4

Ejemplares similares

Olipudase Alfa in Non-CNS Manifestations of Acid Sphingomyelinase Deficiency: A Profile of Its Use
por: Syed, Yahiya Y.
Publicado: (2023)

Clearance of Hepatic Sphingomyelin by Olipudase Alfa Is Associated With Improvement in Lipid Profiles in Acid Sphingomyelinase Deficiency
por: Thurberg, Beth L., et al.
Publicado: (2016)

Correction : Long-term safety and clinical outcomes of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency: two-year results
por: Diaz, George A., et al.
Publicado: (2023)

Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months
por: Wasserstein, Melissa P., et al.
Publicado: (2018)

PB2314: OLIPUDASE ALFA FOR ADULTS WITH ACID SPHINGOMYELINASE DEFICIENCY: IMPROVEMENTS IN CROSSOVER PLACEBO PATIENTS AND FURTHER IMPROVEMENTS IN ORIGINAL OLIPUDASE ALFA PATIENTS AFTER 2 YEARS IN ASCEND TRIAL
por: Villarrubia, J., et al.
Publicado: (2022)

Continued improvement in disease manifestations of acid sphingomyelinase deficiency for adults with up to 2 years of olipudase alfa treatment: open-label extension of the ASCEND trial
por: Wasserstein, Melissa P., et al.
Publicado: (2023)

One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency
por: Diaz, George A., et al.
Publicado: (2021)

One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency
por: Diaz, George A., et al.
Publicado: (2022)

P1483: LONG-TERM IMPACT OF OLIPUDASE ALFA ENZYME REPLACEMENT THERAPY ON SPLEEN VOLUME AND HEMATOLOGIC MANIFESTATIONS IN CHILDREN AND ADULTS WITH CHRONIC ACID SPHINGOMYELINASE DEFICIENCY
por: Villarrubia, Jesus, et al.
Publicado: (2023)

Quantitative Systems Pharmacology Modeling of Acid Sphingomyelinase Deficiency and the Enzyme Replacement Therapy Olipudase Alfa Is an Innovative Tool for Linking Pathophysiology and Pharmacology
por: Kaddi, Chanchala D., et al.
Publicado: (2018)

Long-term safety and clinical outcomes of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency: two-year results
por: Diaz, George A., et al.
Publicado: (2022)

Olipudase alfa enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD): sustained improvements in clinical outcomes after 6.5 years of treatment in adults
por: Lachmann, Robin H., et al.
Publicado: (2023)

Correction to: Perindopril/Indapamide/Amlodipine in Hypertension: A Profile of Its Use
por: Syed, Yahiya Y.
Publicado: (2022)

Correction to: DTaP‑IPV‑HepB‑Hib Vaccine (Hexyon(®)): An Updated Review of its Use in Primary and Booster Vaccination
por: Syed, Yahiya Y.
Publicado: (2019)

Correction to: Regdanvimab: First Approval
por: Syed, Yahiya Y.
Publicado: (2021)

Correction to: Sparsentan: First Approval
por: Syed, Yahiya Y.
Publicado: (2023)

Correction to: Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use
por: Heo, Young-A
Publicado: (2023)

Changes in PCSK 9 and apolipoprotein B100 in Niemann–Pick disease after enzyme replacement therapy with olipudase alfa
por: Garside, Bethanie, et al.
Publicado: (2021)

Correction to: An update on the CNS manifestations of neurofibromatosis type 2
por: Coy, Shannon, et al.
Publicado: (2019)

Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD)
por: McGovern, Margaret M., et al.
Publicado: (2017)

Neonatal cholestasis is an early liver manifestation of children with acid sphingomyelinase deficiency
por: Wang, Neng-Li, et al.
Publicado: (2022)

Correction to: SB8: A Bevacizumab Biosimilar
por: Syed, Yahiya Y.
Publicado: (2020)

Correction to: Nonacog Beta Pegol: A Review in Haemophilia B
por: Syed, Yahiya Y.
Publicado: (2018)

Correction to: Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome
por: Syed, Yahiya Y.
Publicado: (2021)

Correction to: Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome
por: Syed, Yahiya Y.
Publicado: (2021)

Correction to: Lotilaner Ophthalmic Solution 0.25%: First Approval
por: Syed, Yahiya Y.
Publicado: (2023)

Correction to: Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections
por: Syed, Yahiya Y.
Publicado: (2021)

Correction: Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids
por: Syed, Yahiya Y.
Publicado: (2022)

Correction: Estetrol/Drospirenone: A Review in Oral Contraception
por: Lee, Arnold, et al.
Publicado: (2022)

Correction to: Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema
por: Fung, Simon, et al.
Publicado: (2022)

Prevalence of Cancer in Acid Sphingomyelinase Deficiency
por: Mauhin, Wladimir, et al.
Publicado: (2021)

Correction to: Efanesoctocog Alfa: First Approval
por: Keam, Susan J.
Publicado: (2023)

Correction to: Pegaspargase: A Review in Acute Lymphoblastic Leukaemia
por: Heo, Young-A., et al.
Publicado: (2019)

Correction to: Andexanet alfa in the treatment of acute major bleeding related to apixaban and rivaroxaban: a profile of its use in the USA
por: Heo, Young-A
Publicado: (2018)

Apoptosis and signalling in acid sphingomyelinase deficient cells
por: Sillence, Dan J
Publicado: (2001)

Acid Sphingomyelinase Deficiency Ameliorates Farber Disease
por: Beckmann, Nadine, et al.
Publicado: (2019)

Correction to: Andexanet Alfa: First Global Approval
por: Heo, Young-A
Publicado: (2018)

Comparative Analysis of Acid Sphingomyelinase Distribution in the CNS of Rats and Mice Following Intracerebroventricular Delivery
por: Treleaven, Christopher M., et al.
Publicado: (2011)

Correction to: Vestronidase Alfa: A Review in Mucopolysaccharidosis VII
por: McCafferty, Emma H., et al.
Publicado: (2019)

Correction to: Efmoroctocog Alfa: A Review in Haemophilia A
por: Frampton, James E.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lso3ui7q08ufok6bokegaonlmg